Summary:
- Loto Biotech Platform, a biotech startup based in Italy, secured €600K in funding from Scientifica Venture Capital.
- The company plans to use the investment to enhance its operations and development initiatives.
- Loto Biotech focuses on utilizing AI to design siRNA-based pro-drugs for rare genetic disorders, particularly autosomal dominant diseases.
—
Article:
Loto Biotech Platform Secures €600K in Funding for Biotech Development
A promising biotech startup, Loto Biotech Platform, based near L’Aquila, Italy, recently announced a significant milestone in its journey by raising €600K in funding. This investment, provided by Scientifica Venture Capital, will play a crucial role in fueling the company’s expansion plans and furthering its development efforts.
Founded by a talented team including Mattia Capulli, Isabella Baldini, and Riccardo Paone, Loto Biotech is dedicated to leveraging cutting-edge technology in the field of genetic disorders. The company’s primary focus lies in utilizing an innovative AI-driven platform to design siRNA-based pro-drugs, with a specific emphasis on addressing rare autosomal dominant diseases.
Operating from the vibrant ecosystem of Tecnopolo D’Abruzzo, Loto Biotech is set to propel its research and development activities to new heights within Scientifica Lab, a state-of-the-art facility spanning over 4,000 m². This strategic move underscores the company’s commitment to advancing its proprietary technology and making a meaningful impact in the biotech landscape.
As Loto Biotech continues to push boundaries and pioneer advancements in the field of genetic therapeutics, the recent funding injection marks a significant step forward in its mission to tackle challenging rare diseases. With a dedicated team and a clear vision, the company is well-positioned to drive innovation and bring transformative solutions to patients in need.
Stay tuned for more updates on Loto Biotech’s groundbreaking work in the biotech sector.
